These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 23481183)

  • 1. Using macrophage activation to augment immunotherapy of established tumours.
    Fridlender ZG; Jassar A; Mishalian I; Wang LC; Kapoor V; Cheng G; Sun J; Singhal S; Levy L; Albelda SM
    Br J Cancer; 2013 Apr; 108(6):1288-97. PubMed ID: 23481183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.
    Matthews KE; Hermans IF; Roberts JM; Ching LM; Ronchese F
    Immunol Cell Biol; 2006 Aug; 84(4):383-9. PubMed ID: 16834573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
    Downey CM; Aghaei M; Schwendener RA; Jirik FR
    PLoS One; 2014; 9(6):e99988. PubMed ID: 24940883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
    Tao Z; McCall NS; Wiedemann N; Vuagniaux G; Yuan Z; Lu B
    Clin Cancer Res; 2019 Feb; 25(3):1113-1124. PubMed ID: 30352911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dioscin elicits anti-tumour immunity by inhibiting macrophage M2 polarization via JNK and STAT3 pathways in lung cancer.
    Cui L; Yang G; Ye J; Yao Y; Lu G; Chen J; Fang L; Lu S; Zhou J
    J Cell Mol Med; 2020 Aug; 24(16):9217-9230. PubMed ID: 32618105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
    Cuccarese MF; Dubach JM; Pfirschke C; Engblom C; Garris C; Miller MA; Pittet MJ; Weissleder R
    Nat Commun; 2017 Feb; 8():14293. PubMed ID: 28176769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 9. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
    Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
    Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
    De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
    J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage targeting: opening new possibilities for cancer immunotherapy.
    Cassetta L; Kitamura T
    Immunology; 2018 Nov; 155(3):285-293. PubMed ID: 29963704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 16. Hirsutella sinensis Inhibits Lewis Lung Cancer via Tumor Microenvironment Effector T Cells in Mice.
    Fu H; Jin L; Shao X; Li Y; Chen F; Shou Z; Tang X; Ji B; Shou Q
    Am J Chin Med; 2018; 46(4):911-922. PubMed ID: 29754506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization.
    Tan B; Shi X; Zhang J; Qin J; Zhang N; Ren H; Qian M; Siwko S; Carmon K; Liu Q; Han H; Du B; Liu M
    Cancer Res; 2018 Sep; 78(17):4929-4942. PubMed ID: 29967265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal Administration of
    Wang Y; An EK; Kim SJ; You S; Jin JO
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway.
    Xiao X; Li Y; Wang Y; Zhang Y; Chen J; Liu W; Tang J; Yue F; Yang J
    Int Immunopharmacol; 2022 Feb; 103():108427. PubMed ID: 34922249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.